Hoegen Philipp, Lang Clemens, Akbaba Sati, Häring Peter, Splinter Mona, Miltner Annette, Bachmann Marion, Stahl-Arnsberger Christiane, Brechter Thomas, El Shafie Rami A, Weykamp Fabian, König Laila, Debus Jürgen, Hörner-Rieber Juliane
Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.
Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany.
Front Oncol. 2020 Dec 9;10:564857. doi: 10.3389/fonc.2020.564857. eCollection 2020.
To evaluate the potential of cone-beam-CT (CB-CT) guided adaptive radiotherapy (ART) for locally advanced non-small cell lung cancer (NSCLC) for sparing of surrounding organs-at-risk (OAR).
In 10 patients with locally advanced NSCLC, daily CB-CT imaging was acquired during radio- (n = 4) or radiochemotherapy (n = 6) for simulation of ART. Patients were treated with conventionally fractionated intensity-modulated radiotherapy (IMRT) with total doses of 60-66 Gy (pPlan) (311 fraction CB-CTs). OAR were segmented on every daily CB-CT and the tumor volumes were modified weekly depending on tumor changes. Doses actually delivered were recalculated on daily images (dPlan), and voxel-wise dose accumulation was performed using a deformable registration algorithm. For simulation of ART, treatment plans were adapted using the new contours and re-optimized weekly (aPlan).
CB-CT showed continuous tumor regression of 1.1 ± 0.4% per day, leading to a residual gross tumor volume (GTV) of 65.3 ± 13.4% after 6 weeks of radiotherapy (p = 0.005). Corresponding PTVs decreased to 83.7 ± 7.8% (p = 0.005). In the actually delivered plans (dPlan), both conformity (p = 0.005) and homogeneity (p = 0.059) indices were impaired compared to the initial plans (pPlan). This resulted in higher actual lung doses than planned: V was 34.6 ± 6.8% instead of 32.8 ± 4.9% (p = 0.066), mean lung dose was 19.0 ± 3.1 Gy instead of 17.9 ± 2.5 Gy (p = 0.013). The generalized equivalent uniform dose (gEUD) of the lung was 18.9 ± 3.1 Gy instead of 17.8 ± 2.5 Gy (p = 0.013), leading to an increased lung normal tissue complication probability (NTCP) of 15.2 ± 13.9% instead of 9.6 ± 7.3% (p = 0.017). Weekly plan adaptation enabled decreased lung V of 31.6 ± 6.2% (-3.0%, p = 0.007), decreased mean lung dose of 17.7 ± 2.9 Gy (-1.3 Gy, p = 0.005), and decreased lung gEUD of 17.6 ± 2.9 Gy (-1.3 Gy, p = 0.005). Thus, resulting lung NTCP was reduced to 10.0 ± 9.5% (-5.2%, p = 0.005). Target volume coverage represented by conformity and homogeneity indices could be improved by weekly plan adaptation (CI: p = 0.007, HI: p = 0.114) and reached levels of the initial plan (CI: p = 0.721, HI: p = 0.333).
IGRT with CB-CT detects continuous GTV and PTV changes. CB-CT-guided ART for locally advanced NSCLC is feasible and enables superior sparing of healthy lung at high levels of plan conformity.
评估锥形束CT(CB-CT)引导下的自适应放疗(ART)在局部晚期非小细胞肺癌(NSCLC)中对周围危及器官(OAR)的保护潜力。
对10例局部晚期NSCLC患者在放疗(n = 4)或放化疗(n = 6)期间进行每日CB-CT成像以模拟ART。患者接受常规分割调强放疗(IMRT),总剂量为60 - 66 Gy(计划方案,pPlan)(共311次CB-CT扫描)。在每日的CB-CT图像上对OAR进行分割,并根据肿瘤变化每周修改肿瘤体积。在每日图像上重新计算实际给予的剂量(实际方案,dPlan),并使用可变形配准算法进行体素级剂量累积。为模拟ART,使用新的轮廓调整治疗计划并每周重新优化(调整方案,aPlan)。
CB-CT显示肿瘤每天持续退缩1.1±0.4%,放疗6周后残余大体肿瘤体积(GTV)为65.3±13.4%(p = 0.005)。相应的计划靶体积(PTV)降至83.7±7.8%(p = 0.005)。在实际给予的计划(dPlan)中,与初始计划(pPlan)相比,适形指数(p = 0.005)和均匀性指数(p = 0.059)均受损。这导致实际肺剂量高于计划:V20为34.6±6.8%,而非计划的32.8±4.9%(p = 0.066),平均肺剂量为19.0±3.1 Gy,而非17.9±2.5 Gy(p = 0.013)。肺的广义等效均匀剂量(gEUD)为18.9±3.1 Gy,而非17.8±2.5 Gy(p = 0.013),导致肺正常组织并发症概率(NTCP)增加至15.2±13.9%,而非9.6±7.3%(p = 0.017)。每周进行计划调整可使肺V20降至31.6±6.2%(降低3.0%,p = 基于CB-CT的IGRT可检测到GTV和PTV的持续变化。CB-CT引导下的ART用于局部晚期NSCLC是可行的,并且在高计划适形度下能更好地保护健康肺组织。007),平均肺剂量降至17.7±2.9 Gy(降低1.3 Gy,p = 0.005),肺gEUD降至17.6±2.9 Gy(降低1.3 Gy,p = 0.005)。因此,肺NTCP降至10.0±9.5%(降低5.2%,p = 0.005)。通过每周计划调整,由适形指数和均匀性指数表示的靶区体积覆盖情况可得到改善(适形指数:p = 0.007,均匀性指数:p = 0.114),并达到初始计划的水平(适形指数:p = 0.721,均匀性指数:p = 0.333)。
基于CB-CT的IGRT可检测到GTV和PTV的持续变化。CB-CT引导下的ART用于局部晚期NSCLC是可行的,并且在高计划适形度下能更好地保护健康肺组织。